# Press Releases

### Emirates Drug Establishment Approves a new Lung Disease Treatment from Boehringer Ingelheim

June 26, 2026
[Read more](/content/mea/human-health/lung-diseases/emirates-drug-establishment-approves-new-lung-disease-treatment-boehringer-ingelheim/index.html)

### Football’s Yellow Card Becomes a Call for Action on Cardiovascular, Renal, and Metabolic Health at Boehringer Ingelheim’s CRM United Event

November 24, 2025
[Read more](/content/mea/human-health/metabolic-diseases/footballs-yellow-card-becomes-call-action-cardiovascular-renal-and-metabolic-health-boehringer/index.html)

### FIBRONEER™ global phase III trials

June 04, 2025
[Read more](/content/mea/human-health/lung-diseases/pulmonary-fibrosis/fibroneer-global-phase-iii-trials/index.html)

### Boehringer Ingelheim unveiled a breathtaking installation of lungs at the Dubai Miracle Garden to raise awareness for ILD

February 25, 2025
[Read more](/content/mea/human-health/lung-diseases/pulmonary-fibrosis/dubai-miracle-garden-interstitial-lung-disease-awareness-campaign/index.html)

### Boehringer Ingelheim Launches Fast-acting Stroke Medication in the UAE

February 22, 2025
[Read more](/content/mea/human-health/heart-diseases/stroke/boehringer-ingelheim-launches-fast-acting-stroke-medication-uae/index.html)

### Boehringer’s nerandomilast meets primary endpoint in Phase III study

February 10, 2025
[Read more](/content/mea/human-health/lung-diseases/pulmonary-fibrosis/boehringers-nerandomilast-meets-primary-endpoint-phase-iii-study/index.html)

### Saudi Health Council and Boehringer Ingelheim Join Forces to Strengthen Mental Health Policies

January 02, 2025
[Read more](/content/mea/human-health/mental-health/saudi-health-council-and-boehringer-ingelheim-join-forces-strengthen-mental-health-policies/index.html)

### DHA and Boehringer Set Guinness World Records™ Title

November 19, 2024
[Read more](/content/mea/human-health/metabolic-diseases/dha-and-boehringer-set-guinness-world-records-title/index.html)

### Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar

November 11, 2024
[Read more](/content/mea/human-health/lung-diseases/pulmonary-fibrosis/boehringer-launches-treatment-three-interstitial-lung-diseases-qatar/index.html)

### MEDEX and CRM summit discuss latest advances in CRM care

October 21, 2024
[Read more](/content/mea/human-health/heart-diseases/medex-and-crm-summit-discuss-latest-advances-crm-care/index.html)

### Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study

September 17, 2024
[Read more](/content/mea/human-health/lung-diseases/pulmonary-fibrosis/boehringers-nerandomilast-meets-primary-endpoint-pivotal-phase-iii-fibroneer-ipf-study/index.html)